Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. (21st May 2017)

• Record Type: Journal Article
• Authors: Parsons, J. Kellogg; Pierce, John P.; Mohler, James; Paskett, Electra; Jung, Sin‐Ho; Morris, Michael J.; Small, Eric; Hahn, Olwen; Humphrey, Peter; Taylor, John; Marshall, James
• Is Part Of: BJU international. Volume 121:Number 4(2018)
• Page Start: 534
• Page End: 539
• Publication Date: 2017-05-21
• Subjects: diet -- prevention -- outcomes -- active surveillance -- carotenoids -- #ProstateCancer -- #PCSM; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.13890
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objective: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. Methods: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high‐vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi‐squared and Kruskal–Wallis analyses were used to assess between‐group differences at baseline. Results: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd ) age was 64 (6) years and mean (sd ) PSA concentration was 4.9 (2.1) ng/mL. Fifty‐six (12%) participants were African‐American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian‐American. There were no significant between‐group differences for age ( P = 0.98), race/ethnicity ( P = 0.52), geographic region ( P = 0.60), time since prostate cancer diagnosis ( P = 0.85), PSA concentration ( P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre‐planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. Conclusion: The MEAL study shows the feasibility of implementing national, multi‐institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS.